Quince Therapeutics Inc (NASDAQ: QNCX) started the day on Wednesday, with a price increase of 11.02% at $1.31, before settling in for the price of $1.18 at the close. Taking a more long-term approach, QNCX posted a 52-week range of $0.51-$1.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -12.64%. This publicly-traded company’s shares outstanding now amounts to $42.97 million, simultaneously with a float of $32.08 million. The organization now has a market capitalization sitting at $56.69 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7846, while the 200-day Moving Average is $0.9276.
Quince Therapeutics Inc (QNCX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Quince Therapeutics Inc’s current insider ownership accounts for 25.87%, in contrast to 14.00% institutional ownership. According to the most recent insider trade that took place on Aug 30 ’24, this organization’s CEO AND CHIEF MEDICAL OFFICER bought 77,000 shares at the rate of 0.70, making the entire transaction reach 53,900 in total value, affecting insider ownership by 843,941. Preceding that transaction, on Aug 29 ’24, Company’s CEO AND CHIEF MEDICAL OFFICER bought 77,500 for 0.69, making the whole transaction’s value amount to 53,475. This particular insider is now the holder of 766,941 in total.
Quince Therapeutics Inc (NASDAQ: QNCX) Trading Performance Indicators
Let’s observe the current performance indicators for Quince Therapeutics Inc (QNCX). It’s Quick Ratio in the last reported quarter now stands at 6.15. The Stock has managed to achieve an average true range (ATR) of 0.15.
In the same vein, QNCX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.27, a figure that is expected to reach -0.15 in the next quarter.
Technical Analysis of Quince Therapeutics Inc (QNCX)
If we take a close look at the recent performances of Quince Therapeutics Inc (NASDAQ: QNCX), its last 5-days Average volume was 4.28 million that shows progress from its year to date volume of 0.21 million. During the previous 9 days, stock’s Stochastic %D was recorded 54.06% While, its Average True Range was 0.1949.
Raw Stochastic average of Quince Therapeutics Inc (QNCX) in the period of the previous 100 days is set at 62.45%, which indicates a major rise in contrast to 56.36% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 165.51% that was higher than 97.15% volatility it exhibited in the past 100-days period.
